A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

ConclusionCompared to other pan-HER inhibitors, poziotinib showed clinically meaningful efficacy in heavily treated R/M-HNSCC.Clinical trial registration number.NCT02216916.

Source: Cancer Medicine - September 16, 2021 Category: Cancer & Oncology Authors: Ji Hyun Lee, Seong Gu Heo, Beung ‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim Tags: RESEARCH ARTICLE Source Type: research